Fascioliasis drug, Egaten receives FDA approval

Novartis announced this week the approval of Egaten(R) (triclabendazole) by the US Food and Drug Administration (FDA) for the treatment of fascioliasis in patients six years of age and older. Egaten is the only FDA-approved drug for people with the parasitic disease. "Novartis has a long-standing commitment to addressing global health challenges and supporting disease ["]

The post Fascioliasis drug, Egaten receives FDA approval appeared first on Outbreak News Today.